USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Oct 31, 2022 | Sep 2022 | $-0.23 | - | $-0.24 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Oct 31, 2022 | Sep 2022 | $0.00 | - | $0.00 |
Corvus Pharmaceuticals's next earnings date is Monday, Oct 31, 2022 for the fiscal quarter ending Sep 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Sep 2022 | 3 | $-0.23 | $-0.26 | $-0.20 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $-0.84 | $-0.96 | $-0.75 |
| Dec 2023 | 3 | $-1.08 | $-1.58 | $-0.77 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Sep 2022 | 0 / 0 | $-0.23 | $-0.23 | $-0.22 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.84 | $-0.84 | $-0.81 |
| Dec 2023 | 0 / 0 | $-1.08 | $-1.03 | $-1.04 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Sep 2022 | 3 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $0.00 | $0.00 | $0.00 |
| Dec 2023 | 3 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 1, 2022 | Jun 2022 | $-0.18 | - | - |
| May 5, 2022 | Mar 2022 | $-0.15 | $-0.18 | -20.00% |
| Mar 10, 2022 | Dec 2021 | $-0.19 | $-0.20 | -5.26% |
| Nov 1, 2021 | Sep 2021 | $-0.24 | $-0.24 | -1.05% |
| Aug 2, 2021 | Jun 2021 | $-0.31 | $-0.28 | 10.40% |
| Apr 29, 2021 | Mar 2021 | $-0.32 | $-0.34 | -7.94% |
| Mar 25, 2021 | Dec 2020 | $-0.33 | $-0.34 | -4.29% |
| Oct 29, 2020 | Sep 2020 | $-0.22 | $-0.33 | -51.72% |
| Jul 30, 2020 | Jun 2020 | $-0.24 | $-0.36 | -51.58% |
| Apr 30, 2020 | Mar 2020 | $-0.41 | $-0.44 | -8.64% |
| Mar 5, 2020 | Dec 2019 | $-0.31 | $-0.38 | -22.58% |
| Oct 29, 2019 | Sep 2019 | $-0.43 | $-0.37 | 13.29% |
| Aug 1, 2019 | Jun 2019 | $-0.44 | $-0.44 | -0.76% |
| May 9, 2019 | Mar 2019 | $-0.48 | $-0.40 | 16.05% |
| Mar 7, 2019 | Dec 2018 | $-0.50 | $-0.36 | 28.00% |
| Nov 1, 2018 | Sep 2018 | $-0.49 | $-0.36 | 26.03% |
| Aug 2, 2018 | Jun 2018 | $-0.61 | $-0.40 | 34.16% |
| May 3, 2018 | Mar 2018 | $-0.77 | $-0.63 | 18.00% |
| Mar 1, 2018 | Dec 2017 | $-0.77 | $-0.58 | 24.58% |
| Nov 2, 2017 | Sep 2017 | $-0.84 | $-0.62 | 25.82% |
| Aug 3, 2017 | Jun 2017 | $-0.74 | $-0.73 | 1.12% |
| May 4, 2017 | Mar 2017 | $-0.77 | $-0.79 | -2.60% |
| Mar 10, 2017 | Dec 2016 | $-0.55 | $-0.55 | -0.73% |
| Nov 3, 2016 | Sep 2016 | $-0.45 | $-0.51 | -13.33% |
| Aug 4, 2016 | Jun 2016 | $-0.32 | $-0.43 | -36.38% |
| May 5, 2016 | Mar 2016 | $-6.09 | $-5.39 | 11.49% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $-1.00 | $-1.06 | - |
| Mar 25, 2021 | Dec 2020 | $-1.46 | $-1.47 | - |
| Mar 5, 2020 | Dec 2019 | $-1.54 | $-1.59 | - |
| Mar 7, 2019 | Dec 2018 | $-1.83 | $-1.75 | - |
| Mar 1, 2018 | Dec 2017 | $-2.91 | $-2.72 | - |
| Mar 10, 2017 | Dec 2016 | - | $-6.88 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 1, 2022 | Jun 2022 | $0.00 | - | - |
| May 5, 2022 | Mar 2022 | $0.00 | $0.00 | - |
| Mar 10, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Nov 1, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 2, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| Apr 29, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 25, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Oct 29, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Jul 30, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| Apr 30, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Oct 29, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 1, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 9, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Nov 1, 2018 | Sep 2018 | $0.00 | $0.00 | - |
| Aug 2, 2018 | Jun 2018 | $0.00 | $0.00 | - |
| May 3, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Mar 1, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Nov 2, 2017 | Sep 2017 | $0.00 | $0.00 | - |
| Aug 3, 2017 | Jun 2017 | $0.00 | $0.00 | - |
| May 4, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 10, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 3, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 4, 2016 | Jun 2016 | - | $0.00 | - |
| May 5, 2016 | Mar 2016 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Mar 25, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Mar 1, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Mar 10, 2017 | Dec 2016 | - | $0.00 | - |
CRVS's next earnings date is Monday, Oct 31, 2022 for the fiscal quarter ending Sep 30, 2022.
According to analysts, the average EPS estimation for Corvus Pharmaceuticals's next quarterly earnings is $-0.23, with a low EPS estimation of $-0.26, and a high estimation of $-0.20.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.23, the last 2 month trend is $-0.23, and the 3 month trend is $-0.22.
Based on analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Corvus Pharmaceuticals's previous earnings date was Aug 1, 2022 for its fiscal quarter ended Jun 30, 2022.
Corvus Pharmaceuticals's previous annual earnings date was Mar 10, 2022 for its fiscal year ended Dec 31, 2021.
CRVS's earnings per share (EPS) was $-1.06, missing the consensus analysts forecast of $-1.00 by 6.00% , and higher than the previous year's EPS (Dec 2020) by -27.93%.
Revenues were $0.00.
The company reported a net income of $-43.24M.
Corvus Pharmaceuticals reported a free cash flow of $-36.72M for its fiscal year, compared to $-34.85M a year ago.
The company ended the fiscal year with $3.65M in total debt, an increase of 57.88% compared to the previous year.
